GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012

GAITHERSBURG, Md., Aug. 2, 2012 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) will report financial results for the second quarter ended June 30, 2012 on Thursday, August 9, 2012, before the U.S. financial markets open.  The announcement will be followed by a webcast and conference call at 10:00 a.m. EDT to discuss the Company's second quarter financial results and business outlook.

To listen to the live conference call, please dial 877-558-0567 (U.S. or Canada) or 706-643-4980 (international) and use the following Conference ID: 47686784. An audio replay of the conference call will be available starting at 1:00 p.m. EDT on August 9, 2012 through August 16, 2012. To listen to the audio replay, dial 855-859-2056 or 404-537-3406 and use Conference Replay ID: 47686784.

To access the webcast or the replay, go to www.genvec.com, click on "Investors and Media," and click on "Events and Presentations."

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health, we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.


Retail Investor and Media Contact:

GenVec, Inc.

Douglas J. Swirsky

(240) 632-5510

[email protected]

Institutional Investor Contact:

S.A. Noonan Communications

Susan A. Noonan

(212) 966-3650

[email protected]





SOURCE GenVec, Inc.

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.